{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:02:34Z","timestamp":1745766154710},"reference-count":15,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jns.2014.06.022","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T20:16:41Z","timestamp":1403554601000},"page":"1-2","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumefactive multiple sclerosis and fingolimod"],"prefix":"10.1016","volume":"344","author":[{"given":"Jesus","family":"Lovera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Villemarette-Pittman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jns.2014.06.022_bb0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.wnl.0000344567.51394.e3","article-title":"Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report","volume":"72","author":"Leypoldt","year":"2009","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jns.2014.06.022_bb0010","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e31824c46ad","article-title":"Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?","volume":"78","author":"Castrop","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2014.06.022_bb0015","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1177\/1352458512458009","article-title":"Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal","volume":"18","author":"Daelman","year":"2012","journal-title":"Mult Scler"},{"issue":"19","key":"10.1016\/j.jns.2014.06.022_bb0020","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1212\/WNL.0b013e3182735cb3","article-title":"Tumefactive multiple sclerosis lesions under fingolimod treatment","volume":"79","author":"Visser","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2014.06.022_bb0025","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod","volume":"18","author":"Jander","year":"2012","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.jns.2014.06.022_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00415-012-6744-7","article-title":"Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients","volume":"260","author":"Ghezzi","year":"2012","journal-title":"J Neurol"},{"issue":"19","key":"10.1016\/j.jns.2014.06.022_bb0035","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","article-title":"Tumefactive MS lesions under fingolimod: a case report and literature review","volume":"81","author":"Pilz","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2014.06.022_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e31829deeb4","article-title":"Re: Tumefactive multiple sclerosis lesions under fingolimod treatment","volume":"81","author":"Kinney","year":"2013","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.jns.2014.06.022_bb0045","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1212\/WNL.0b013e3182735c7a","article-title":"Severe relapses under fingolimod treatment prescribed after natalizumab","volume":"79","author":"Centonze","year":"2012","journal-title":"Neurology"},{"issue":"13 Pt 2","key":"10.1016\/j.jns.2014.06.022_bb0050","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2014.06.022_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1352458510392098","article-title":"Observations during an elective interruption of natalizumab treatment: a post-marketing study","volume":"17","author":"Borriello","year":"2011","journal-title":"Mult Scler"},{"issue":"22","key":"10.1016\/j.jns.2014.06.022_bb0060","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2014.06.022_bb0065","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458512439438","article-title":"MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis","volume":"18","author":"Grimaldi","year":"2012","journal-title":"Mult Scler"},{"issue":"14","key":"10.1016\/j.jns.2014.06.022_bb0070","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.jns.2014.06.022_bb0075","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1400392X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X1400392X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T01:01:09Z","timestamp":1538528469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X1400392X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":15,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0022510X1400392X"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.06.022","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumefactive multiple sclerosis and fingolimod","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}